Although indices of activity for systemic lupus erythematosus have been developed and validated, a disease staging system requires the measurement of severity as well. We have constructed such a scale, the Lupus Severity of Disease Index (Lupus SDI). Accepted clinical, pathologic and physiologic classification schemes were employed to validate this index at two separate research institutions. The Lupus SDI allows homogenization of patient populations for the purposes of research and, possibly, for case mix adjustment.
Fries JF, Weyl S., Holman HREstimating prognosis in systemic lupus erythematosus. Am J Med1974; 57: 561-5.
2.
Rothfield NFSurvival in systemic lupus erythematosus. JAMA1978; 239(17): 1741-2.
3.
Horn SD, Horn RAReliability and validity of the severity of illness index. Med Care1986; 24(2): 159-78.
4.
McMahon LF, Billi JEMeasurement of severity of illness and the Medicare Prospective Payment System: state of the art and future directions. J Gen Int Med1988; 3: 482-90.
5.
Cretin S., Worthman LGAlternative Systems for Case Mix Classification in Health Care Financing (R-3457-HCFA) . Santa Monica, CA: The RAND Corporation , 1986.
6.
Jencks SJ, Dobson A.Refining case-mix adjustment. The research evidence. N Engl J Med1987; 317 (11): 679-86.
7.
Cohen J.Statistical Power Analysis. New York: Academic Press, 1977.
8.
Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271-7.
9.
Liang MH, Socher SA, Larson MG, Schur PHReliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum1989; 32(9): 1107-18.
10.
Ginzler EM, Diamond HS, Weiner M. et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum1982; 25(6): 601 -11.
11.
Ginzler EM, Diamond HS, Weiner M. et al. A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum1982; 25(6): 612-7.
12.
Wiedemann HP , Matthay R.Pulmonary manifestations of the collagen vascular diseases. Clin Chest Med1989; 10(4): 677-722.
13.
Boelaert J. , Morel-Maroger L., Mery J.Renal insufficiency in lupus nephritis. Adv Nephrol1974; 4: 249-89.
14.
Morel-Maroger L., Mery J., Droz D. et al. The course of lupus nephritis: contribution of serial renal biopsies. Adv Nephrol1976 ; 6: 79-118.
15.
Munro BH. Visintainer MA, Page EBStatistical Methods for Health Care Research . Philadelphia: J.B. Lippincott Company, 1986: 64-78.
16.
Liang MH, Socher SA, Roberts WN, Esdaile JMMeasurement of systemic lupus erythematosus activity in clinical research . Arthritis Rheum1988; 31(7): 817-25.
17.
Liang MH, Stern S., Esdaile JMSystemic lupus erythematosus activity. An operational definition. Rheum Dis Clin N Am1988; 14(1): 57-66.
18.
Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JEDiffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int1984; 25: 689-95.
19.
Nossent HC, Henzen-Logmans SC, Vroom TM, Berden Jhm, Swaak Tjg.Contribution of renal biopsy data in predicting outcome in lupus nephritis . Arthritis Rheum1990; 33(7): 970-7.
20.
Swaak Ajg, Groenwold J., Bronsveld W.Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus . Ann Rheum Dis1986; 45: 359-66.
21.
ter Borg EJ , Horst G., Hummel EJ, Limburg PC, Kallenberg Cgm.Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum1990; 33(5): 634-43.
